Early Recognition and Prevention During the Psychotic Prodrome. After more than five decades of increasingly refined psychopharmacologic developments, schizophrenia has remained one of the most severe and disabling disorders in medicine. Since interventions after a first schizophrenia episode have not been able to alter the generally chronic and relapsing disease course (Robinson et al. 2004), early intervention and prevention of schizophrenia are a vital goal. Initial, retrospective studies that demonstrated presence of a symptomatic prepsychotic illness phase of clinically relevant severity and duration (Hafner et al. 1999) provided the practical basis for early identification efforts. Several lines of evidence further supported the potential utility of early interventions for the schizophrenia prodrome. These include an increasing appreciation that schizophrenia is a neurodevelopmental disorder characterized by early developmental delays and problems, and that is further associated with a significant functional decline and brain morphological changes (Correll and Kane 2004;Sawa and Snyder, 2002;Woods 1998). Moreover, the duration of untreated psychosis (Marshall et al. 2005), and number of relapses have been associated with decreased grey matter and worse functional outcomes, even after controlling for potentially relevant confounders (Perkins et al. 2005). Importantly, brain morphological changes have also been demonstrated during the transition from prodromal psychosis to full blown psychosis (Pantelis et al. 2003), suggesting that early intervention may be a potential vehicle to effectively interrupt biological processes involved in the development of psychosis and its adverse functional consequences. Prodromal schizophrenia research conducted over the past ten years at our Center and others has further consolidated the evidence that early identification and intervention studies during the schizophrenia prodrome are possible. Early recognition programs have identified high risk samples with conversion rates to psychosis between 10 and 40% over one to two years (Yung et al. 2008). In the largest study to date by the North American Prodromal Longitudinal Study (NAPLS) group of which Dr. Cornblatt at our Center is one of the PIs, a conversion rate of 35.3% over 2.5 years was reported (Cannon et al. 2008). These conversion rates to psychosis are 10-40 times the prevalence rate observed in the general population and far greater than the expected incidence rate during such a brief time period (Eaton 1999).

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH090590-04
Application #
8463877
Study Section
Special Emphasis Panel (ZMH1-ERB-N)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
4
Fiscal Year
2013
Total Cost
$47,942
Indirect Cost
$19,061
Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
110565913
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Nagendra, Arundati; Schooler, Nina R; Kane, John M et al. (2018) Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study. Schizophr Res 193:64-68
Karlsgodt, Katherine H; Bato, Angelica A; Ikuta, Toshikazu et al. (2018) Functional Activation During a Cognitive Control Task in Healthy Youth Specific to Externalizing or Internalizing Behaviors. Biol Psychiatry Cogn Neurosci Neuroimaging 3:133-140
Browne, Julia; Estroff, Sue E; Ludwig, Kelsey et al. (2018) Character strengths of individuals with first episode psychosis in Individual Resiliency Training. Schizophr Res 195:448-454
Robinson, Delbert G; Schooler, Nina R; Correll, Christoph U et al. (2018) Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. Am J Psychiatry 175:169-179
Baumel, Amit; Baker, Justin; Birnbaum, Michael L et al. (2018) Summary of Key Issues Raised in the Technology for Early Awareness of Addiction and Mental Illness (TEAAM-I) Meeting. Psychiatr Serv 69:590-592
John, Majnu; Lencz, Todd; Malhotra, Anil K et al. (2018) A simulations approach for meta-analysis of genetic association studies based on additive genetic model. Meta Gene 16:143-164
Kishimoto, Taishiro; Hagi, Katsuhiko; Nitta, Masahiro et al. (2018) Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophr Bull 44:603-619
DeRosse, Pamela; Nitzburg, George C; Blair, Melanie et al. (2018) Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults. Schizophr Res 195:385-390
Lyall, A E; Pasternak, O; Robinson, D G et al. (2018) Greater extracellular free-water in first-episode psychosis predicts better neurocognitive functioning. Mol Psychiatry 23:701-707
Shafritz, Keith M; Ikuta, Toshikazu; Greene, Allison et al. (2018) Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response. Brain Imaging Behav :

Showing the most recent 10 out of 120 publications